Edoxaban accepted by NICE for stroke prevention in atrial fibrillation

The direct thrombin inhibitor edoxaban (Lixiana) has been recommended by NICE, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Further information
NICE technology appraisal TA355

Patients are eligible to receive the treatment on the NHS if they have one or more risk factors, including:

  • congestive heart failure
  • hypertension
  • diabetes
  • prior stroke or transient ischaemic attack
  • age 75 years or older.

In August, NICE approved edoxaban for use in treating and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more